Home › Funds › Trails Edge Capital Partners, LP › TRAX
Trails Edge Capital Partners, LP position in TRAX
FIRST TRACKS BIOTHERAPEUTICS · Health Care
Trails Edge Capital Partners, LP reported holding 814,000 shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$28.8M, representing 4.15% of its reported portfolio and ranking #9 among its reported holdings. Trails Edge Capital Partners, LP has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's TRAX position evolved
Trails Edge Capital Partners, LP first disclosed a stake in TRAX in Q2 2026 at 1,514,000 shares (US$30.5M). Across 2 filings, Trails Edge Capital Partners, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 814,000 shares valued at US$28.8M — a reduction of -700,000 shares quarter over quarter.. Notable position changes include a 46% trim in Q3 2026 (shares rose 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.51M | $30.46M | New |
| Q3 2026 | 814.00K | $28.85M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRAX and 13F data
TRAX (FIRST TRACKS BIOTHERAPEUTICS) is a Health Care company. 181 other funds we track also report a position in TRAX — the largest reported positions include EcoR1 Capital, LLC (US$112.5M), TCG Crossover Management, LLC (US$102.6M), Affinity Asset Advisors, LLC (US$73.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRAX
- EcoR1 Capital, LLC 3.17M sh · $112.50M · Q3 2026
- TCG Crossover Management, LLC 2.90M sh · $102.61M · Q3 2026
- Affinity Asset Advisors, LLC 2.08M sh · $73.72M · Q3 2026
- Sanofi 821.92K sh · $29.13M · Q3 2026
- STEMPOINT CAPITAL LP 649.92K sh · $23.03M · Q3 2026
- 683 Capital Management, LLC 600.00K sh · $21.26M · Q3 2026
- Vestal Point Capital, LP 1.01M sh · $20.38M · Q2 2026
- Sofinnova Investments, Inc. 383.59K sh · $13.59M · Q3 2026
- Palo Alto Investors LP 603.49K sh · $12.14M · Q2 2026
- Ally Bridge Group (NY) LLC 284.29K sh · $5.72M · Q2 2026
- Opaleye Management Inc. 65.00K sh · $1.31M · Q2 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held TRAX?
Trails Edge Capital Partners, LP has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Trails Edge Capital Partners, LP's current position in TRAX?
As of Q3 2026, Trails Edge Capital Partners, LP holds 814.00K shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $28.85M, representing 4.15% of its reported portfolio and ranking #9.
Has Trails Edge Capital Partners, LP been buying or selling TRAX?
In the latest 13F filing (Q3 2026), Trails Edge Capital Partners, LP reduced its position in TRAX.
Which other funds hold TRAX?
Other major institutional holders of TRAX include EcoR1 Capital, LLC, TCG Crossover Management, LLC, Affinity Asset Advisors, LLC, among 181 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.